Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company's respiratory business has shown remarkable performance, leading to a continuous improvement in profitability [2][12] - The company has successfully expanded its product offerings and market reach, particularly in respiratory disease testing and HPV testing [12][13] - Financial forecasts indicate a recovery in revenue and profit growth from 2024 onwards, with a projected CAGR of 14.47% over three years [13] Financial Data and Valuation - Revenue for 2023 is reported at 1.007 billion yuan, a decrease of 84.39% year-on-year, while the net profit is 364 million yuan, down 81.22% [11] - The company expects revenues of 1.533 billion yuan in 2024, with a growth rate of 52.22%, and net profit of 294 million yuan, reflecting a decline of 19.30% [3][13] - The company's EBITDA for 2023 is 478 million yuan, with projections of 579 million yuan for 2024 [3] - The gross margin for 2023 is reported at 71.54%, an increase of 12.71 percentage points, driven by the rapid growth of high-margin conventional reagents [16] Product Performance - The revenue from conventional reagents reached 783 million yuan in 2023, a year-on-year increase of 149.33%, primarily due to increased demand for respiratory disease testing [12] - The respiratory product revenue exceeded 400 million yuan, showing a significant year-on-year growth of 680% [12] - The company has successfully won bids for HPV testing products in 25 provinces, with two products ranking first in procurement volume, indicating potential for future revenue growth [12] Future Outlook - The company is expected to achieve revenues of 1.536 billion yuan in 2024, 2.036 billion yuan in 2025, and 2.493 billion yuan in 2026, with respective growth rates of 52.22%, 32.80%, and 22.43% [3][13] - The projected net profit for 2024 is 294 million yuan, followed by 438 million yuan in 2025 and 546 million yuan in 2026, with growth rates of -19.30%, 49.11%, and 24.64% respectively [3][13]

Investment Rating - The report maintains a "Buy" rating for the company [8]. Core Views - The high-speed rail passenger transport continues to show strong growth, with the company's performance improving significantly [2][3]. - In 2023, the company achieved a total revenue of 40.683 billion yuan, a year-on-year increase of 110.40%, and a net profit attributable to shareholders of 11.546 billion yuan, recovering from a loss of 0.576 billion yuan in the same period of 2022 [2][3]. - The company plans to repurchase shares worth 1 billion yuan, reflecting confidence in future growth [5]. Financial Performance - In Q1 2024, the company reported a revenue of 10.106 billion yuan, up 13.06% year-on-year, and a net profit of 2.963 billion yuan, an increase of 33.11% [5]. - The total passenger volume for the year 2023 reached 53.252 million, a 209.1% increase compared to the previous year [3]. - The company's main business cost for 2023 was 22.052 billion yuan, a year-on-year increase of 31.91%, with energy expenses rising significantly due to increased passenger volume and train operations [4]. Revenue and Profit Forecast - The projected revenues for 2024, 2025, and 2026 are 44.719 billion yuan, 48.804 billion yuan, and 53.269 billion yuan, respectively, with growth rates of 9.92%, 9.14%, and 9.15% [6]. - The forecasted net profits for the same years are 13.452 billion yuan, 15.449 billion yuan, and 17.463 billion yuan, with growth rates of 16.52%, 14.85%, and 13.03% [6]. - The earnings per share (EPS) are expected to be 0.27 yuan, 0.31 yuan, and 0.36 yuan for 2024, 2025, and 2026, respectively [6]. Valuation - The report assigns a target price of 6.21 yuan based on a 23x price-to-earnings (P/E) ratio for 2024 [6].

Investment Rating - The investment rating for the company is currently not explicitly stated in the provided documents, but the report suggests a focus on continuous monitoring of the company's performance due to its ongoing transformation and growth potential [6]. Core Views - The company achieved a significant year-on-year sales growth of 39.3% in April 2024, with total sales reaching 153,000 vehicles [2]. - Cumulative sales for the first four months of 2024 reached 629,000 vehicles, reflecting a 46.9% increase compared to the same period last year [2]. - The report highlights the acceleration of the company's transformation towards new energy vehicles, with a notable increase in the penetration rate of such vehicles to 33.6% in April 2024, up by 6.8 percentage points year-on-year [3]. Summary by Sections Sales Performance - In April 2024, the company's sales by brand included 118,000 vehicles for the Geely brand, 16,000 for the Zeekr brand, and 19,000 for the Lynk & Co brand [3]. - The new energy vehicle sales reached 51,000 units in April, marking a 75.0% increase year-on-year, with a cumulative total of 196,000 units sold in the first four months of 2024, up 120.4% year-on-year [3]. New Product Launches - The report notes that several new models were launched in April 2024, including the Lynk & Co 07 EM-P and various models from the Zeekr brand, which are expected to support future sales growth [4]. Export Growth - The company exported 38,000 vehicles in April 2024, a 74.7% increase year-on-year, with exports accounting for 24.9% of total sales [5]. - Cumulative exports for the first four months of 2024 reached 125,000 vehicles, reflecting a 68.8% increase year-on-year [5]. Financial Forecasts - The company is projected to achieve revenues of 223.2 billion, 266.3 billion, and 306.6 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of 24.6%, 19.3%, and 15.1% [6]. - Net profit forecasts for the same period are 7.08 billion, 8.53 billion, and 9.98 billion yuan, with growth rates of 33.4%, 20.5%, and 16.9% [6].

Investment Rating - The report maintains a "Buy" rating for Qianhe Condiment (603027) with a target price of 21.76 RMB [6][8] Core Views - The company's revenue and net profit grew significantly in 2023, with revenue reaching 3.207 billion RMB (up 31.62% YoY) and net profit reaching 530 million RMB (up 54.22% YoY) [3] - In Q1 2024, revenue grew 9.28% YoY to 895 million RMB, while net profit increased 6.66% YoY to 155 million RMB, slightly below expectations [3] - The company's channel expansion strategy continues to drive revenue growth, with a net increase of 1,020 distributors in 2023, particularly in central and western regions [4] - Product upgrades and cost reduction measures are expected to improve profitability, with gross margin increasing by 0.59 percentage points to 37.15% in 2023 [5] Financial Performance Revenue and Profit - 2023 revenue: 3.207 billion RMB (up 31.62% YoY) [3] - 2023 net profit: 530 million RMB (up 54.22% YoY) [3] - 2024E revenue: 3.768 billion RMB (up 17.49% YoY) [6] - 2024E net profit: 658 million RMB (up 24.06% YoY) [6] Product Performance - Soy sauce revenue: 2.04 billion RMB (up 34.85% YoY), accounting for 63.6% of total revenue [4] - Vinegar revenue: 422 million RMB (up 11.75% YoY), accounting for 13.2% of total revenue [4] - Gross margin for soy sauce: 37.59% (up 0.44 percentage points YoY) [4] - Gross margin for vinegar: 39.07% (up 2.05 percentage points YoY) [4] Regional Performance - Central region revenue: 449 million RMB (up 80.97% YoY) [4] - Eastern region revenue: 712 million RMB (up 30.94% YoY) [4] - Southern region revenue: 208 million RMB (up 26.00% YoY) [4] - Northern region revenue: 567 million RMB (up 27.09% YoY) [4] - Western region revenue: 1.229 billion RMB (up 23.77% YoY) [4] Valuation and Forecast - 2024E PE ratio: 24.2x [6] - 2024E target price: 21.76 RMB [6] - 2024-2026 revenue CAGR: 16.49% [6] - 2024-2026 net profit CAGR: 19.81% [6] Industry and Market Position - The company operates in the food and beverage industry, specifically in the condiment fermentation sector [8] - It has a strong market position with a focus on natural fermentation, zero-additive, and healthy products [5] - The company is expanding its national market presence, particularly in central and western regions [4]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified in the report [2]. Core Views - The company reported steady growth in diagnostic and treatment demand, with a robust profitability maintained [3]. - In 2023, the company achieved a revenue of 4.013 billion yuan, a year-on-year increase of 24.12%, and a net profit of 666 million yuan, up 29.6% [3]. - The company’s outpatient visits exceeded 1.86 million, a growth of 21%, and surgical procedures surpassed 370,000, increasing by approximately 23% [4]. - The company’s main business gross margin reached 49.04%, an increase of 0.88 percentage points year-on-year, with significant improvements in cataract and posterior segment business margins [5]. - The company is expanding its global ophthalmic medical service network through both organic growth and acquisitions [6]. Financial Summary - The company’s projected revenues for 2024-2026 are 4.776 billion, 5.674 billion, and 6.679 billion yuan, with year-on-year growth rates of 19.0%, 18.8%, and 17.7% respectively [7]. - The net profit forecasts for the same period are 853 million, 1.084 billion, and 1.362 billion yuan, with growth rates of 28.1%, 27.1%, and 25.7% respectively [7]. - The company’s earnings per share (EPS) are expected to be 1.02, 1.29, and 1.62 yuan per share for 2024, 2025, and 2026 respectively [7]. - The company’s total share capital is 840 million shares, with a circulating market value of approximately 8.799 billion yuan [8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [8]. Core Insights - The company has shown steady growth in performance, with a significant recovery in rigid demand, as evidenced by a 26.43% year-on-year increase in revenue to 20.367 billion yuan in 2023 and a 33.07% increase in net profit to 3.359 billion yuan [2][3]. - The company's outpatient and surgical volumes have steadily increased, with outpatient visits reaching 15.0164 million, a 34.26% increase, and surgical procedures totaling 1.1837 million, up 35.95% year-on-year [3][4]. - The recovery in rigid demand has notably driven business growth, particularly in refractive surgery, which generated 7.431 billion yuan in revenue, a 17.27% increase, and cataract surgery, which saw a 55.24% increase in revenue to 3.327 billion yuan [4]. - The company's strategic "1+8+N" layout continues to advance the establishment of regional eye care centers, with significant revenue growth in Northeast and East China regions, achieving 1.794 billion yuan and 3.113 billion yuan respectively [5]. Financial Summary - The company forecasts revenue growth from 26.771 billion yuan in 2024 to 41.650 billion yuan in 2026, with corresponding net profits expected to rise from 4.424 billion yuan to 6.910 billion yuan during the same period [6][7]. - The earnings per share (EPS) is projected to increase from 0.47 yuan in 2024 to 0.74 yuan in 2026, reflecting a strong growth trajectory [6][7]. - The company’s financial metrics indicate a healthy outlook, with a projected P/E ratio decreasing from 27.4 in 2024 to 17.5 in 2026, suggesting improved valuation [7].

证券研究报告 公 2024年05月10日 司 报 告 通策医疗(600763) │ 行 业： 医药生物/医疗服务 公 投资评级： 买入（维持） 司 当前价格： 66.54元 年 诊疗需求稳健增长，各项业务稳步发展 目标价格： 79.04元 报 点 事件： 评 基本数据 公司发布 2023 年年报及 2024 年一季报。2023 全年，公司实现营业收入 总股本/流通股本(百万股) 320.64/320.64 28.47亿元，同比增长4.70%；归母净利润5.00亿元，同比减少8.72%；扣 流通A股市值(百万元) 21,335.39 非净利润4.81亿元，同比减少8.37%。2024Q1，公司实现营业收入7.08亿 每股净资产(元) 12.40 元，同比增长 5.03%；归母净利润 1.73亿元，同比增长 2.51%；扣非净利 资产负债率(%) 28.88 润1.70亿元，同比增长4.20%。 一年内最高/最低(元) 120.29/52.24 ➢ 诊疗需求稳健增长，各项业务稳步发展 2023 年，公司口腔医疗门诊量达 335.33 万人次，公司大综合业务实现收 股价相对走势 入7.56亿元，同比增长8.34%； ...

证券研究报告 公 2024年05月09日 司 报 告 锦浪科技(300763) │ 行 业： 电力设备/光伏设备 公 投资评级： 增持（下调） 司 当前价格： 58.39元 海外去库存周期业绩承压，电站业务快速成长 年 目标价格： 63.28元 报 点 事件： 评 基本数据 2024年4月28日，公司发布2023年报及2024年一季报，2023年公司实 总股本/流通股本(百万股) 400.69/321.53 现营业收入 61.01 亿元，同比增长 3.59%，实现归母净利润 7.79 亿元,同 流通A股市值(百万元) 18,774.41 比减少 26.46%，实现经营活动现金净流量 3.83 亿元，同比减少 60.17%， 每股净资产(元) 19.45 实现销售毛利率32.38%，同比下降1.14pct，单位盈利水平基本稳定。 资产负债率(%) 64.35 2024Q1公司实现营业收入13.97亿元，同比/环比分别-15.56%/-4.29%，实 一年内最高/最低(元) 116.85/51.11 现归母净利润 0.20 亿元，同比/环比分别-93.74%/-27.15%,实现销售毛利 率24.24%,同比/环 ...

证券研究报告 公 2024年05月09日 司 报 告 通威股份(600438) │ 行 业： 电力设备/光伏设备 公 投资评级： 增持（维持） 司 当前价格： 22.79元 竞争加剧影响业绩，硅料竞争优势稳固 年 目标价格： 25.65元 报 点 事件： 评 基本数据 2024年4月29日，公司发布2023年报及2024年一季报，2023年公司实 总股本/流通股本(百万股) 4,501.97/4,501.97 现营业收入1391.04亿元，同比减少2.33%，实现归母净利润135.74亿元, 流通A股市值(百万元) 102,599.99 同比减少47.25%，实现经营活动现金净流量306.79亿元，同比减少29.98%， 每股净资产(元) 13.06 实现销售毛利率26.44%，同比下降11.73pct，报告期内，受供需关系变化 资产负债率(%) 59.27 影响，硅料价格大幅下降，是影响公司业绩的主要原因。 一年内最高/最低(元) 39.65/21.09 2024Q1 公司实现营业收入195.70 亿元，同比减少41.13%，实现归母净利 润-7.87亿元，同比减少109.15%,实现经营活动现金净流量-1 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 52.27 CNY, based on a current price of 33.90 CNY [6]. Core Insights - The company achieved a revenue of 8.826 billion CNY in 2023, representing a year-on-year growth of 8.17%. The net profit attributable to shareholders was 439 million CNY, up 3.38% year-on-year. However, in Q1 2024, the revenue decreased by 6.75% to 2.139 billion CNY, and the net profit fell by 8.71% to 127 million CNY [3][15]. - The company is focusing on enhancing its computing power services and has secured significant contracts, including a comprehensive maintenance service project with China Mobile for 2023-2026, maintaining a leading market share in 15 out of 21 provinces [4][14]. Financial Performance Summary - In 2023, the company reported a revenue of 8.826 billion CNY, with a growth rate of 8.17%. The EBITDA was 579 million CNY, and the net profit was 439 million CNY, with a growth rate of 3.39% [16]. - The forecast for 2024-2026 indicates revenues of 10.852 billion CNY, 13.153 billion CNY, and 15.457 billion CNY, with respective growth rates of 22.95%, 21.20%, and 17.52%. The net profit is expected to be 587 million CNY, 707 million CNY, and 814 million CNY, with growth rates of 33.84%, 20.48%, and 15.08% [15][16]. - The earnings per share (EPS) are projected to be 2.09 CNY, 2.52 CNY, and 2.90 CNY for 2024, 2025, and 2026, respectively, with a three-year compound annual growth rate (CAGR) of 22.89% [15]. Business Development - The company is actively developing its computing power services, having established partnerships with several supercomputing centers. It is also raising funds through convertible bonds to build a cloud computing center, which will be the largest in Guangxi [14][15]. - The company has made significant progress in its intelligent maintenance services, winning key projects and expanding its market presence in various provinces [4][14].